Risk factors for major bleeding in patients with atrial fibrillation and CKD G3-G5D on oral anticoagulants
- PMID: 39421237
- PMCID: PMC11483581
- DOI: 10.1093/ckj/sfae206
Risk factors for major bleeding in patients with atrial fibrillation and CKD G3-G5D on oral anticoagulants
Abstract
Background: Patients with chronic kidney disease (CKD) and atrial fibrillation (AF) on oral anticoagulants (OACs) are at high risk of bleeding. Determinants of major bleeding risk in OAC users with AF and CKD are not well established and available bleeding score systems do not perform well in CKD. This study aims to present risk factors associated with major bleeding in a Swedish cohort of OAC-treated patients with CKD G3-5D.
Methods: We conducted a Swedish register-based cohort study including patients with AF and CKD G3-5D on warfarin or direct OACs (DOACs) between 2009 and 2018. Data were collected from high-quality registers including the Swedish Renal Registry and Auricula, a register for AF and OACs. Risk factors for major bleeding were investigated with Cox regression analysis.
Results: Of 2453 included patients, 59% were on warfarin (time in therapeutic range 67%) and 41% on DOACs. Major bleeding rates were 8.9/100 patient-years. Factors associated with increased bleeding risk were glomerular filtration rate category, G5/5D versus G3 {hazard ratio [HR] 1.92 [95% confidence interval (CI) 1.43-2.56]}, previous gastrointestinal bleeding [HR 1.77 (95% CI 1.39-2.25)], previous other bleeding [HR 1.33 (95% CI 1.09-1.62)], congestive heart failure [HR 1.36 (95% CI 1.11-1.68)], male sex [HR 1.28 (95% CI 1.03-1.60)] and vascular disease [HR 1.35 (95% CI 1.01-1.79)].
Conclusion: Patients with AF and G3-5D on OACs are at a high risk of bleeding. Previous major bleeding and kidney failure are strongly associated with major bleeding. The present study also shows an association between OAC-associated bleeding and male sex, congestive heart failure and vascular disease. Knowledge about determinants of bleeding in advanced CKD is essential when deciding on when to anticoagulate or not.
Keywords: anticoagulants; atrial fibrillation; bleeding; chronic kidney disease; dialysis.
© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.
Conflict of interest statement
A.S. has received consultancy or lecture fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer. F.W. and H.R. declare no conflicts of interest.
Figures
Similar articles
-
Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D.Clin Kidney J. 2023 Jan 5;16(5):835-844. doi: 10.1093/ckj/sfad004. eCollection 2023 May. Clin Kidney J. 2023. PMID: 37151425 Free PMC article.
-
Warfarin treatment quality and outcomes in patients with non-valvular atrial fibrillation and CKD G3-G5D.Thromb Res. 2023 Sep;229:131-138. doi: 10.1016/j.thromres.2023.07.003. Epub 2023 Jul 8. Thromb Res. 2023. PMID: 37453255
-
Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D.Clin Kidney J. 2022 Jan 28;15(6):1169-1178. doi: 10.1093/ckj/sfac022. eCollection 2022 Jun. Clin Kidney J. 2022. PMID: 35664263 Free PMC article.
-
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.Cochrane Database Syst Rev. 2017 Nov 6;11(11):CD011373. doi: 10.1002/14651858.CD011373.pub2. Cochrane Database Syst Rev. 2017. PMID: 29105079 Free PMC article. Review.
-
Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies.Chest. 2016 Apr;149(4):951-9. doi: 10.1378/chest.15-1719. Epub 2016 Jan 12. Chest. 2016. PMID: 26378611 Review.
References
-
- Hindricks G, Potpara T, Dagres Net al. . 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373–498. - PubMed
-
- Fu EL, Desai RJ, Paik JMet al. . Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: nationwide US cohort study. Am J Kidney Dis 2024;83:293–305.e1. - PubMed
LinkOut - more resources
Full Text Sources